A164 SINGLE-CELL RNASEQ INDICATES INCREASE IN COLONIC REGULATORY MACROPHAGES DURING CITROBACTER RODENTIUM INFECTIOUS COLITIS

TL;DR

This study explores the role of regulatory macrophages in Citrobacter rodentium-induced colitis and finds that these cells may help defend against infection.

Contribution

The study reveals a previously overlooked antimicrobial role of M2 macrophages during Citrobacter rodentium infection.

Findings

M2 macrophages increase in the colon during Citrobacter rodentium infection and express antimicrobial genes.

Treatment with IL-4-treated macrophages does not worsen infection severity or delay bacterial clearance.

Infection induces increased levels of inflammatory markers regardless of macrophage treatment.

Abstract

Citrobacter rodentium (CR) is a murine attaching and effacing enteric bacterial pathogen that induces colitis and mimics enteropathogenic and enterohemorrhagic E. coli in humans. Studies of macrophages during CR infection have focused on proinflammatory functions, paying less attention to M2 or regulatory macrophages. We have shown that IL-4-treated macrophages (M(IL4)) have promising potential as a novel anti-colitic therapy using chemical-induced colitis in mice. However, any benefit of M(IL4)s in infectious colitis is unknown. This study tests the hypothesis that regulatory macrophages, specifically M(IL4)s, limit the severity of CR-infectious colitis.

i. Determine if M2 macrophages increase in the colon of CR infected mice.

ii. Assess the impact of M(IL4) treatment in CR infection severity and inflammation.

C57Bl/6 mice were orally infected with CR (5x108 CFU), and colons were collected during the colonization, expansion, and clearance phases (0, 3, 8, 21 days post-infection, DPI) for single-cell RNAseq to examine immune profiles and differentially expressed genes (DEG). The effect of M(IL4) treatment was assessed through ip. delivery of M(IL4)s (106cells) two days before CR infection followed by analysis of bacterial shedding and colonic histopathology. Inflammation was measured by neutrophil-mediated lipocalin-2 in feces by ELISA and RT-qPCR for mRNA expression of the anti-microbial peptide, REGIIIγ, and Th1 cytokine, IFN-γ.

Peaking at 3 DPI, there was a significant increase in arginase1+ Relma+ Ym1+ M2 macrophages in the colon of CR-infected mice compared to proinflammatory M1 subsets. These M2-type cells showed upregulated expression of Cxcl9 and Acod1 mRNA, which possess antimicrobial activity essential in mitigating CR infection. Pretreatment with M(IL4)s did not exacerbate CR infection as bacterial shedding and histopathology scores (n=13) were similar in both groups, with all mice clearing CR by 18 DPI (n=5). Infection with CR was accompanied by increased fecal lipocalin and tissue REGIIIγ and IFNγ mRNA, independent of M(IL4) treatment (n=13).

This study suggests a formerly unappreciated antimicrobial role of M2 macrophages in the defense against CR. While M(IL4) treatment did not improve the outcome of infection with CR, neither did it exaggerate the severity of the infection, suggesting that the adoption of M(IL4) therapy for IBD would not increase the individual’s susceptibility to enteric infection.

NRC